ORIGINAL ARTICLE

Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone

T Ueda¹, N Araki², M Mano³, A Myoui¹, S Joyama¹, S Ishiguro³, H Yamamura⁴, K Takahashi⁴, I Kudawara⁵, H Yoshikawa¹

¹ Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2–2 Yamada-oka, Suita, Osaka 565–0871, Japan
² Department of Orthopaedic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 540-0006, Japan
³ Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases
⁴ Department of Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases
⁵ Department of Orthopaedic Surgery, Osaka National Hospital, Osaka 540-0006, Japan

Correspondence to:
Correspondence to:
Dr T Ueda, Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2–2 Yamada-oka, Suita, Osaka 565–0871, Japan;
uedat{at}ort.med.osaka-u.ac.jp

Background/Aims: Malignant fibrous histiocytoma (MFH) of bone, a relatively rare primary malignant bone tumour, is a distinct clinicopathological entity as opposed to MFH derived from soft tissue. Although the true histogenesis of this condition is still controversial, a considerable number of cases of MFH in soft tissue show positive immunohistochemical reactivity for muscle markers such as desmin, common muscle actin (HHF35), and smooth muscle actin (SMA), suggesting that MFH cells are myofibroblastic in nature.

Methods: This study investigated immunoreactivity for several different muscle markers in 19 cases of MFH of bone together with reverse transcription polymerase chain reaction (RT-PCR) analysis on frozen tissue samples that were available in four cases, and compared the data with those found in 11 cases of osteosarcoma and 11 cases of soft tissue MFH treated over the same period.

Results: Immunohistochemistry revealed that MFH of bone showed relatively frequent expression of smooth muscle markers, including calponin (nine cases), -SMA (nine cases), and SM22 (18 cases), and this was confirmed by RT-PCR analysis. However, only one, two, and three cases of MFH of bone showed positive staining for desmin, MyoD1, and HHF35, respectively. Similarly, 11 osteosarcoma cases were relatively frequently positive for -SMA (five cases), calponin (four cases), and SM22 (seven cases), and less frequently positive for desmin (one case), MyoD1 (none), and HHF35 (none). In contrast, very few MFH of soft tissue cases (n = 11) showed positive reactivity for all of these muscle markers. It has recently been reported that human bone marrow stromal cells also express various kinds of smooth muscle markers including -SMA and calponin.

Conclusions: These results suggested that MFH of bone may derive from mesenchymal stromal cells in bone marrow and has a more myofibroblastic differentiation than soft tissue MFH.

Keywords: malignant fibrous histiocytoma of bone; smooth muscle markers; immunohistochemistry; reverse transcription polymerase chain reaction analysis

Abbreviations: ABC, avidin–biotin complex; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HHF35, common muscle actin; MFH, malignant fibrous histiocytoma; RT-PCR, reverse transcription polymerase chain reaction; -SMA, smooth muscle actin

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hasegawa, T, Hasegawa, F, Hirose, T, Sano, T, Matsuno, Y (2003). Expression of smooth muscle markers in so called malignant fibrous histiocytomas. J. Clin. Pathol. 56: 666-671 [Abstract] [Full Text]